Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI: Current and future applications

Thomas A. Hope, Ali Afshar-Oromieh, Matthias Eiber, Louise Emmett, Wolfgang P. Fendler, Courtney Lawhn-Heath, Steven Rowe

Research output: Contribution to journalArticle

Abstract

OBJECTIVE. The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer. CONCLUSION. PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.

Original languageEnglish (US)
Pages (from-to)286-294
Number of pages9
JournalAmerican Journal of Roentgenology
Volume211
Issue number2
DOIs
StatePublished - Aug 1 2018

Keywords

  • PET
  • PET/MRI
  • Prostate cancer
  • Prostate-specific membrane antigen

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI: Current and future applications'. Together they form a unique fingerprint.

  • Cite this